| Symbol | RLAY |
|---|---|
| Name | RELAY THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 399 BINNEY STREET,2ND FLOOR, CAMBRIDGE, Massachusetts, 02139, United States |
| Telephone | +1 617 370-8837 |
| Fax | — |
| — | |
| Website | https://www.relaytx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001812364 |
| Description | Relay Therapeutics Inc is a clinical-stage, precision medicines company transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company is advancing its pipeline of medicines to address targets in precision oncology, including its lead product candidates, RLY-4008 and RLY-1971, as well as its PI3Ka mutant selective program, known as the RLY-PI3K1047 program. Its initiated a Phase 1 clinical trial for RLY-1971 in patients with advanced solid tumors in the first quarter of 2020 and a first-in-human clinical trial of RLY-4008 enriched for patients with advanced solid tumors having oncogenic FGFR2 alterations in the third quarter of 2020. Additional info from NASDAQ: |
Patel Sanjiv 🔴 sold 48.2K shares of Relay Therapeutics, Inc. (RLAY) at $20.33 Transaction Date: Aug 17, 2026 | Filing ID: 355502
Read moreCatinazzo Thomas 🔴 sold 17.7K shares of Relay Therapeutics, Inc. (RLAY) at $19.74 Transaction Date: Aug 14, 2026 | Filing ID: 355493
Read moreNew Form SCHEDULE 13G/A - Relay Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001831942-26-000036 <b>Size:</b> 14 KB
Read moreNew Form SCHEDULE 13G/A - Relay Therapeutics, Inc. <b>Filed:</b> 2026-08-10 <b>AccNo:</b> 0001193125-26-342308 <b>Size:</b> 10 KB
Read moreNew Form SCHEDULE 13G/A - Relay Therapeutics, Inc. <b>Filed:</b> 2026-08-07 <b>AccNo:</b> 0000315066-26-002255 <b>Size:</b> 11 KB
Read moreRelay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates
Read more📋 SEKAR KATHIRESAN (Director) plans to sell 30K shares of RELAY THERAPEUTICS, INC. (at $18.79 each, total $564K) Filed: Jul 31, 2026 | ID: 007457
Read moreCatinazzo Thomas 🔴 sold 1.5K shares of Relay Therapeutics, Inc. (RLAY) at $18.61 Transaction Date: Jul 28, 2026 | Filing ID: 326144
Read moreRahmer Peter 🔴 sold 748 shares of Relay Therapeutics, Inc. (RLAY) at $18.61 Transaction Date: Jul 28, 2026 | Filing ID: 326142
Read moreBergstrom Donald A 🔴 sold 2.2K shares of Relay Therapeutics, Inc. (RLAY) at $18.61 Transaction Date: Jul 28, 2026 | Filing ID: 326137
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07584226 | A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors | Phase1 | Advanced NRAS-Mutant Melanoma | Recruiting | 2026-03-09 | 2029-12-31 | ClinicalTrials.gov |
| NCT06982521 | Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatm… | Phase3 | PIK3CA Mutation | Recruiting | 2025-08-26 | 2031-12-31 | ClinicalTrials.gov |
| NCT06789913 | A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Ch… | Phase2 | PIK3CA-Related Overgrowth Spectrum (PROS) | Recruiting | 2025-06-13 | 2031-10-01 | ClinicalTrials.gov |
| NCT05759949 | First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumo… | Phase1 | PIK3CA Mutation | Completed | 2023-03-29 | 2025-04-11 | ClinicalTrials.gov |
| NCT05216432 | First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single… | Phase1 | PIK3CA Mutation | Recruiting | 2021-12-08 | 2027-04-30 | ClinicalTrials.gov |
| NCT04622527 | A Study to Assess Virtual Reality by Healthcare Providers: A Pilot Study | Na | Anxiety | Completed | 2021-01-01 | 2022-12-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| RLY-2608 | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Fulvestrant | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| Capivasertib | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| Zovegalisib | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| Fulvestrant | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| Capivasertib | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| RLY-2608 | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| RLY-8161 | Other | Phase PHASE1 | Advanced NRAS-Mutant Melanoma | RECRUITING | NCT07584226 |
| Placebo | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| RLY-2608 | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Fulvestrant | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| Capivasertib | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| RLY-2608 | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| RLY-8161 | Other | Phase PHASE1 | Advanced NRAS-Mutant Melanoma | RECRUITING | NCT07584226 |
| RLY-8161 | Other | Phase PHASE1 | NRAS Mutation | RECRUITING | NCT07584226 |
| RLY-8161 | Other | Phase PHASE1 | NRAS Mutation | RECRUITING | NCT07584226 |
| RLY-8161 | Other | Phase PHASE1 | NRAS Mutation | RECRUITING | NCT07584226 |
| RLY-8161 | Other | Phase PHASE1 | NRAS Mutation | RECRUITING | NCT07584226 |
| RLY-8161 | Other | Phase PHASE1 | NRAS Mutation | RECRUITING | NCT07584226 |
| RLY-8161 | Other | Phase PHASE1 | NRAS Mutation | RECRUITING | NCT07584226 |
| Fulvestrant | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| Capivasertib | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| RLY-2608 | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| Fulvestrant | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| Capivasertib | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| RLY-2608 | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| Fulvestrant | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| Capivasertib | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| RLY-2608 | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| Fulvestrant | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| Capivasertib | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| RLY-2608 | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| Fulvestrant | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| Capivasertib | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| RLY-2608 | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| Placebo | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| RLY-2608 | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Placebo | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| RLY-2608 | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Placebo | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| RLY-2608 | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Placebo | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| RLY-2608 | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Placebo | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| RLY-2608 | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Placebo | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| RLY-2608 | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Placebo | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| RLY-2608 | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Placebo | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| RLY-2608 | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Placebo | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| RLY-2608 | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Placebo | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| RLY-2608 | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Placebo | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| RLY-2608 | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Placebo | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| RLY-2608 | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Placebo | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| RLY-2608 | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Placebo | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| RLY-2608 | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Placebo | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| RLY-2608 | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Placebo | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| RLY-2608 | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Random assigned paradigm viewing order | Other | Approved | Anxiety | COMPLETED | NCT04622527 |
| Abemaciclib | Other | Phase PHASE1 | PIK3CA Mutation | COMPLETED | NCT05759949 |
| Ribociclib | Other | Phase PHASE1 | PIK3CA Mutation | COMPLETED | NCT05759949 |
| Palbociclib | Other | Phase PHASE1 | PIK3CA Mutation | COMPLETED | NCT05759949 |
| Fulvestrant | Other | Phase PHASE1 | PIK3CA Mutation | COMPLETED | NCT05759949 |
| RLY-5836 | Other | Phase PHASE1 | PIK3CA Mutation | COMPLETED | NCT05759949 |
| PF-07220060 300 mg | Other | Phase PHASE1 | PIK3CA Mutation | RECRUITING | NCT05216432 |
| PF-07220060 100mg | Other | Phase PHASE1 | PIK3CA Mutation | RECRUITING | NCT05216432 |
| Ribociclib 600mg | Other | Phase PHASE1 | PIK3CA Mutation | RECRUITING | NCT05216432 |
| Ribociclib 400mg | Other | Phase PHASE1 | PIK3CA Mutation | RECRUITING | NCT05216432 |
| Palbociclib 125mg | Other | Phase PHASE1 | PIK3CA Mutation | RECRUITING | NCT05216432 |
| Fulvestrant | Other | Phase PHASE1 | PIK3CA Mutation | RECRUITING | NCT05216432 |
| RLY-2608 | Other | Phase PHASE1 | PIK3CA Mutation | RECRUITING | NCT05216432 |
| Fulvestrant | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| Capivasertib | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| RLY-2608 | Other | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| Placebo | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| RLY-2608 | Other | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Capivasertib | DRUG | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| Placebo | DRUG | Phase PHASE2 | PIK3CA-Related Overgrowth Spectrum (PROS) | RECRUITING | NCT06789913 |
| Abemaciclib | DRUG | Phase PHASE1 | PIK3CA Mutation | COMPLETED | NCT05759949 |
| Ribociclib | DRUG | Phase PHASE1 | PIK3CA Mutation | COMPLETED | NCT05759949 |
| Palbociclib | DRUG | Phase PHASE1 | PIK3CA Mutation | COMPLETED | NCT05759949 |
| RLY-5836 | DRUG | Phase PHASE1 | PIK3CA Mutation | COMPLETED | NCT05759949 |
| PF-07220060 300 mg | DRUG | Phase PHASE1 | PIK3CA Mutation | RECRUITING | NCT05216432 |
| PF-07220060 100mg | DRUG | Phase PHASE1 | PIK3CA Mutation | RECRUITING | NCT05216432 |
| Ribociclib 600mg | DRUG | Phase PHASE1 | PIK3CA Mutation | RECRUITING | NCT05216432 |
| Ribociclib 400mg | DRUG | Phase PHASE1 | PIK3CA Mutation | RECRUITING | NCT05216432 |
| Palbociclib 125mg | DRUG | Phase PHASE1 | PIK3CA Mutation | RECRUITING | NCT05216432 |
| Fulvestrant | DRUG | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| RLY-2608 | DRUG | Phase PHASE3 | PIK3CA Mutation | RECRUITING | NCT06982521 |
| Random assigned paradigm viewing order | OTHER | Approved | Anxiety | COMPLETED | NCT04622527 |